WK5Assignment: Patient Education for Children and Adolescents
Patient education is an effective tool in supporting compliance and treatment for a diagnosis. It is important to consider effective ways to educate patients and their families about a diagnosis—such as coaching, brochures, or videos—and to recognize that the efficacy of any materials may differ based on the needs and learning preferences of a particular patient. Because patients or their families may be overwhelmed with a new diagnosis, it is important that materials provided by the practitioner clearly outline the information that patients need to know.
The Assignment
**TOPIC: Week 5 topic is Premenstrual Dysphoric disorder.
· For this Assignment, you will pretend that you are a contributing writer to a health blog.
· You are tasked with explaining important information about an assigned mental health disorder in language appropriate for child/adolescent patients and/or their caregivers.
To Prepare
· By Day 1, your Instructor will assign a mood or anxiety disorder diagnosis for you to use for this Assignment.
· Research signs and symptoms for your diagnosis, pharmacological treatments, nonpharmacological treatments, and appropriate community resources and referrals.
The Assignment (detailed rubric at the end of this doc.)
· In a 300- to 500-word blog post written for a patient and/or caregiver audience,
· explain signs and symptoms for your diagnosis, pharmacological treatments, nonpharmacological treatments,
· and appropriate community resources and referrals.
Submit your Assignment.
Required Readings
Hilt, R. J., & Nussbaum, A. M. (2016). DSM-5 pocket guide for child and adolescent mental health. American Psychiatric Association Publishing.
· Chapter 3, “Common Clinical Concerns”
· Chapter 7, “A Brief Version of DSM-5″
· Chapter 8, “A stepwise approach to Differential Diagnosis”
· Chapter 10, “Selected DSM-5 Assessment Measures”
· Chapter 11, “Rating Scales and Alternative Diagnostic Systems”
Shoemaker, S. J., Wolf, M. S., & Brach, C. (2014). The patient education materials assessment tool (PEMAT) and user’s guide. Agency for Healthcare Research and Quality. https://www.ahrq.gov/sites/default/files/publications/files/pemat_guide.pdf
Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.
· Chapter 60, “Anxiety Disorders”
· Chapter 61, “Obsessive Compulsive Disorder”
· Chapter 62, “Bipolar Disorder in Childhood”
· Chapter 63, “Depressive Disorders in Childhood and Adolescence”
Medication Review
Review the FDA-approved use of the following medicines related to treating mood and anxiety disorders in children and adolescents.
Bipolar depression Bipolar disorder
lurasidone (age 10–17) olanzapine-fluoxetine combination (age 10–17) aripiprazole (age 10–17) asenapine (for mania or mixed episodes, age 10–17) lithium (for mania, age 12–17) olanzapine (age 13–17) quetiapine (age 10–17) risperidone (age 10–17)
Generalized anxiety disorder Depression
duloxetine (age 7–17) escitalopram (age 12–17) fluoxetine (age 8–17)
Obsessive-compulsive disorder
clomipramine (age 10–17) fluoxetine (age 7–17) fluvoxamine (age 8–17) sertraline (age 6–17)